New York [US]November 4 (ANI): Researchers at Memorial Sloan Kettering Cancer Center (MSK) and Mount Sinai have discovered treatments that may help patients with multiple myeloma, a blood cancer, who have tried CAR-T immunotherapy but who experienced relapses.
Chimeric Antigen Receptor T-cell therapy, or CAR-T for short, uses immune cells called T-cells to treat multiple myeloma by modifying them in the lab to allow them to recognize and eradicate cancer cells. Although it is a breakthrough therapy for this deadly malignancy, some patients who undergo CAR-T therapy relapse and are left with no other viable treatment options.
Read also | Selena Gomez reveals she may not have children in the future because of her bipolar disorder medication.
When several myeloma patients relapsed after BCMA-led CAR-T, a form of CAR-T cell therapy that targets the BCMA protein on cancerous plasma cells to treat multiple myeloma, they were treated with a variety of therapies different, according to a recent study. published in the journal Blood in November.
Researchers have found that alternative T-cell therapies, such as bispecific antibodies and various forms of CAR-T cell therapy, appear to have the most pronounced efficacy in permanently eradicating the disease in these relapsed patients.
Read also | Air pollution causes more disability than tobacco smoke, says former AIIMS director Dr. Randeep Guleria.
“The results of this study will serve as a benchmark for future prospective clinical studies aimed at improving the outcomes of patients who progress after CAR-T,” said a lead study author, Samir Parekh, MD, director of translational research. in Multiple Myeloma and Co-Lead of the Cancer Clinical Investigation Program at the Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai.
“This is the first study to report the results of different treatment options offered to a large cohort of patients who relapsed after anti-BCMA CAR-T treatment. It is one of the most urgent and unmet needs in patients with myeloma and therefore of great importance. interest to the hematology community.
This retrospective study examined disease characteristics, post-relapse medications, and therapeutic responses of 79 patients. Median overall patient survival is currently around 18 months.
In these patients, stem cell transplantation has also had some success. Depending on the characteristics of each patient’s cancer, different drug combinations may also be administered with varying degrees of success, the study found.
The Tisch Cancer Institute and MSK supported the patients.
“We are encouraged that the subsequent use of other novel immune therapies like a second CAR-T cell therapy or a bispecific antibody was feasible and led to long-lasting responses in patients,” said Sham Mailankody, MBBS. , Associate Physician, MSK, and senior author on the paper. “We look forward to continuing this work and unlocking the full potential of immune therapies for patients with multiple myeloma.” (ANI)
(This is an unedited and auto-generated story from syndicated newsfeed, LatestLY staff may not have edited or edited the body of the content)